Norroy Bioscience Co. Ltd. has prepared and tested peptide-drug conjugates comprising a fibroblast activation protein α (FAP)-targeting moiety linked to a radionuclide-labeled metal chelating agent for use as positron emission tomography (PET) imaging agents in the diagnosis and/or treatment of cancer.
A University of California patent describes new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1), DNA repair and serine/threonine-protein kinase ATR inhibitors potentially useful for the treatment of cancer.
Synnovation Therapeutics Inc. has discovered new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligases binding moiety coupled to nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2)-targeting moiety potentially useful for the treatment of cancer.
Zhize Tongkang (Guangzhou) Biotechnology Co. Ltd. has divulged new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting claudin 6 (CLDN6) linked to a camptothecin derivative potentially useful for the treatment of cancer and fibrosis.
Zhongshan Laibo Ruichen Biomedicine Co. Ltd. has patented new polypeptides and their drug conjugates potentially useful for the treatment of osteoporosis.
Hutchmed Ltd. has identified new antibody-drug conjugates (ADCs) comprising an antibody targeting EGFR (HER1; erbB1) linked to cytotoxic drug potentially useful for the treatment of cancer and autoimmune diseases.
Scinnohub Pharmaceutical Co. Ltd. has disclosed new biazacycloalkane compounds acting as menin (MEN1)/KMT2A (MLL) and/or MEN1 (M327I mutant)/KMT2A (MLL) and/or MEN1 (T349M mutant)/KMT2A (MLL) interaction inhibitors potentially useful for the treatment of cancer and diabetes.
Open Source Therapeutics Co. Ltd. has reported new nitrogen-containing heterocyclic compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors potentially useful for the treatment of cancer.
RSS